Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET–CT: a comparative study

Beheshti, Mohsen; Vali, Reza; Waldenberger, Peter; Fitz, Friedrich; Nader, Michael; Loidl, Wolfgang; Broinger, Gabriele; Stoiber, Franz; Foglman, Ignac; Langsteger, Werner

doi:10.1007/s00259-008-0788-z

Cited by 260 publications

(102 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Obviously, there seems to be no uniform radiological criteria for assessing intercorporal fusion by plain radiographs or CT [10,[15][16][17][18]. 18F-fluoride PET/(CT) on the contrary has mostly been used in the assessment of malignant bone abnormalities [19][20][21][22][23]. However, promising results are also found in benign bone disorders, e.g.…”

Section: Discussionmentioning

confidence: 99%

Assessment of successful incorporation of cages after cervical or lumbar intercorporal fusion with [(18)F]fluoride positron-emission tomography/computed tomography

Fischer

Zweifel²,

Treyer

et al. 2010

Eur Spine J

View full text Add to dashboard Cite

The purpose of this study is to assess the successful incorporation of cages in patients after cervical or lumbar intercorporal fusion with positron-emission tomography/computed tomography (PET/CT). Twenty patients (14 female and 6 male; mean age 58 years, age range 38-73 years) with 30 cervical (n = 13) or lumbar (n = 17) intercorporal fusions were prospectively enrolled in this study. Time interval between last intercorporal intervention and PET/CT ranged from 2 to 116 months (mean 63; median 77 months). IRB approval was obtained for all patients, and written informed consent was obtained from all patients. About 30 min prior to PET/CT scanning, 97-217 MBq (mean 161 MBq) 18F-fluoride were administered intravenously. Patients were imaged in supine position on a combined PET/CT system (Discovery RX/STE, 16/64 slice CT, GE Healthcare). 3D-PET emission data were acquired for 1.5 and 2 min/bed position, respectively, and reconstructed by a fully 3D iterative algorithm (VUE Point HD) using low-dose CT data for attenuation correction. A dedicated diagnostic thin-slice CT was optionally acquired covering the fused region. Areas of increased 18F-fluoride uptake around cages were determined by one double-board certified radiologist/ nuclear physician and one board certified radiologist in consensus. In 12/20 (60%) patients, increased 18F-fluoride uptake around cages was observed. Of the 30 intercorporal fusions, 15 (50%) showed increased 18F-fluoride uptake. Median time between intervention and PET/CT examination in cages with increased uptake was 37 months (2-116 months), median time between intervention and PET/CT examination in those cages without increased uptake was 91 months (19-112 months), p (Wilcoxon) = 0.01 (one-sided). 14/29 (48%) cages with a time interval [ 1 year between intervention and PET/CT scan showed an increased uptake. In conclusion, PET/CT frequently shows increased 18F-fluoride uptake in cervical and lumbar cages older than 1 year (up to almost 8 years in cervical cages and 10 years in lumbar cages) possibly indicating unsuccessful fusion due to increased stress/ microinstability.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of successful incorporation of cages after cervical or lumbar intercorporal fusion with [(18)F]fluoride positron-emission tomography/computed tomography

Fischer

Zweifel²,

Treyer

et al. 2010

Eur Spine J

View full text Add to dashboard Cite

show abstract

“…Fluoride has high affinity for bone, with increased uptake reflecting osteoblastic activity [28]. Studies have suggested that fluoride PET may have better sensitivity, specificity, and accuracy in detecting skeletal metastasis compared to choline PET [30].…”

Section: Imagingmentioning

confidence: 99%

Management of Biochemical Recurrence After Primary Treatment of Prostate Cancer: A Systematic Review of the Literature

et al. 2013

View full text Add to dashboard Cite

Context: Despite excellent cancer control with the treatment of localized prostate cancer (PCa), some men will experience a recurrence of disease. The optimal management of recurrent disease remains uncertain. Objective: To systematically review recent literature regarding management of biochemical recurrence after primary treatment for localized PCa. Evidence acquisition: A comprehensive systematic review of the literature was performed from 2000 to 2012 to identify articles pertaining to management after recurrent PCa. Search terms included prostate cancer recurrence, salvage therapy, radiorecurrent prostate cancer, post HIFU, post cryoablation, postradiation, and postprostatectomy salvage. Studies were selected according to Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines and required to provide a comprehensive description of primary and secondary treatments along with outcomes. Evidence synthesis: The data from 32 original publications were reviewed. The most common option for local salvage therapy after radical prostatectomy (RP) was radiation. Options for local salvage therapy after primary radiation included RP, brachytherapy, and cryotherapy. Different definitions of recurrence and risk profiles among patients make comparative assessment among salvage treatment modalities difficult. Triggers for intervention and factors predicting response to salvage therapy vary. Conclusions: Radiation therapy (RT) after RP can provide durable prostate-specific antigen (PSA) responses in a sizeable percentage of men, especially when given early (ie, PSA <1 ng/ml). Though a few studies suggest improvements in mortality, prospective randomized trials are needed and underway. The role of salvage treatment after RT is less clear.

show abstract

“…13,17,[22][23][24][25][26][27][28] Husarik et al 13 reported the sensitivity of choline-PET/CT was 70 per cent with a PSA ≤2ng/ml at the time of the scan, compared with 86 per cent when PSA >2ng/ml. Another group showed a sensitivity of 20 per cent with PSA ≤1ng/ml, 44 per cent for PSA 1-5ng/ml and 82 per cent for PSA >5ng/ml.…”

Section: Trends In Urology and Men's Health May/june 2014mentioning

confidence: 99%

“…The specificity benefit results from the absence of tracer uptake in chronic degenerative lesions that may be falsely positive on bone scans. 17 It has been suggested that PET/CT imaging can identify bone metastases at an earlier marrow-only stage of involvement, before such disease can be identified on CT imaging. 4 No evidence has yet shown the superiority of choline-PET over standard systemic staging imaging techniques in establishing the presence of metastatic disease at diagnosis.…”

Section: M-stagingmentioning

confidence: 99%

Current status of choline‐PET and prostate cancer

Taylor

Kirby

Hughes

et al. 2014

Trends Urol & Men's Health

View full text Add to dashboard Cite

show abstract

Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET–CT: a comparative study

Cited by 260 publications

References 15 publications

Assessment of successful incorporation of cages after cervical or lumbar intercorporal fusion with [(18)F]fluoride positron-emission tomography/computed tomography

Assessment of successful incorporation of cages after cervical or lumbar intercorporal fusion with [(18)F]fluoride positron-emission tomography/computed tomography

Management of Biochemical Recurrence After Primary Treatment of Prostate Cancer: A Systematic Review of the Literature

Current status of choline‐PET and prostate cancer

Contact Info

Product

Resources

About